JAZZ vs. REGN: Jazz Pharmaceuticals vs. Regeneron Pharmaceuticals Stock Comparison

Company Profile

Jazz Pharmaceuticals (JAZZ) and Regeneron Pharmaceuticals (REGN) both fall under the Pharmaceuticals, Biotechnology & Life Sciences industry group, but JAZZ is classified in Pharmaceuticals while REGN is classified in Biotechnology.

Price Performance

Cumulative Growth

Trailing Returns

Calendar-Year Returns

Performance Metrics

Risk Profile

Drawdown History

Return Distribution

Risk Metrics

Risk-Adjusted Performance

Risk-Return Positioning

Risk-Adjusted Metrics

Profitability

Regeneron Pharmaceuticals (REGN) at 14.95% sits in the top ROE quartile, while Jazz Pharmaceuticals (JAZZ) at 5.05% is closer to the peer norm — stronger capital efficiency for REGN.

Regeneron Pharmaceuticals (REGN) at 28.51% converts revenue to bottom-line profit above its industry’s benchmark range, while Jazz Pharmaceuticals (JAZZ) at 4.37% keeps roughly the typical share for its industry.

Both Jazz Pharmaceuticals (JAZZ) at 30.17% and Regeneron Pharmaceuticals (REGN) at 40.46% convert sales into operating profit at a top-quartile rate, pointing to tighter cost discipline before financing and tax.

Profitability Metrics

Growth

Both Jazz Pharmaceuticals (JAZZ) at 4.88% and Regeneron Pharmaceuticals (REGN) at 0.99% land near their industries' usual revenue growth ranges, so top-line momentum looks broadly in line with peers on both sides.

Regeneron Pharmaceuticals (REGN) at 8.19% is around its peer norm for EPS growth, while Jazz Pharmaceuticals (JAZZ) at -167.51% drops into the bottom quartile, signaling weaker earnings momentum.

Growth Metrics

Financial Strength

Regeneron Pharmaceuticals (REGN) at 3.35 keeps current ratio within its industry’s typical mid-range, while Jazz Pharmaceuticals (JAZZ) at 1.82 runs in the tighter-liquidity quartile — a thinner cushion against current liabilities for JAZZ.

Regeneron Pharmaceuticals (REGN) at 0.08 carries an industry-typical debt-to-equity mix, while Jazz Pharmaceuticals (JAZZ) at 1.35 uses more debt funding than most peers.

Financial Strength Metrics

Dividends

Jazz Pharmaceuticals (JAZZ) pays no dividend (yield 0.00%) — it may be reinvesting, using buybacks, or simply not returning cash through dividends. Meanwhile Regeneron Pharmaceuticals (REGN) reports a yield of 0.41%, ranking against industry peers normally.

Jazz Pharmaceuticals (JAZZ) pays no dividend (payout 0.00%) — it may be reinvesting, using buybacks, or simply not returning cash through dividends. Meanwhile Regeneron Pharmaceuticals (REGN) reports a payout of 8.18%, ranking against industry peers normally.

Dividend Metrics

Valuation

Regeneron Pharmaceuticals (REGN) at 19.99 is near its industry’s usual P/E ratio, while Jazz Pharmaceuticals (JAZZ) at 69.46 sits in the richer quartile — JAZZ needs stronger growth or earnings quality to justify the premium.

On P/S ratio, both Jazz Pharmaceuticals (JAZZ) at 3.19 and Regeneron Pharmaceuticals (REGN) at 5.54 are priced roughly in line with their industries — neither looks cheap nor rich on a sales basis.

On P/B ratio, both Jazz Pharmaceuticals (JAZZ) at 3.59 and Regeneron Pharmaceuticals (REGN) at 2.71 are valued close to their industries’ norm against book — neither stands out from peers.

Valuation Metrics